Ryanodex and Standard of Care
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Exertional Heat Stroke
Conditions
Exertional Heat Stroke
Trial Timeline
Aug 19, 2018 → Aug 14, 2019
NCT ID
NCT03600376About Ryanodex and Standard of Care
Ryanodex and Standard of Care is a phase 3 stage product being developed by Eagle Pharmaceuticals for Exertional Heat Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT03600376. Target conditions include Exertional Heat Stroke.
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03600376 | Phase 3 | Completed |
Competing Products
1 competing product in Exertional Heat Stroke
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Definity | Lantheus Holdings | Phase 2/3 | 35 |